Key Highlights
- The FDA held a public meeting on testosterone use in menopausal women, with no FDA-approved therapy currently available for women.
- Experts were split between calls for a female-specific product and concerns about insufficient long-term safety data.
- The UK, Australia, New Zealand and South Africa have approved testosterone products specifically for women, while the US has not.
- The public comment period following the meeting closes on October 19, with hundreds of submissions already received.
No Approved Option for Women
US health regulators weighing testosterone use in menopausal women heard from experts at a public meeting this week, with some arguing a female-specific product was needed while others pointed to gaps in evidence on the hormone’s broader benefits and long-term safety. The meeting, which the FDA said could help guide future research and drug development, comes as a growing number of women turn to testosterone to manage menopause symptoms.
There is no FDA-approved testosterone therapy for women, despite years of off-label use to treat hypoactive sexual desire disorder, or HSDD. The UK, Australia, New Zealand and South Africa have approved or licensed testosterone products specifically for women.
Calls for Action
Assistant Secretary for Health Admiral Brian Christine said in his opening remarks that it was unacceptable that U.S. women lack an approved testosterone therapy while such treatments are available elsewhere. "Something’s wrong with that," he said, urging the FDA to "get this done." Physicians who currently prescribe testosterone to women typically rely on low doses of products approved for men, often dividing existing formulations or using compounded versions.
A deputy director at a federal child health institute said women deserved Options "formulated and dosed specifically for them." Hundreds of public comments have been submitted ahead of the meeting, many from women describing improved libido, energy and quality of life while using testosterone.
Evidence Remains Limited
Not all experts agreed that a female-specific product would resolve the underlying questions. The director of a major university menopause care program said evidence supports testosterone only for postmenopausal women with HSDD, with insufficient data to recommend it for mood, cognition or general well-being. Oral testosterone is not recommended due to unfavorable effects on cholesterol levels, she noted.
Testosterone has been reviewed by the FDA multiple times for use in women but has never been approved, due to a lack of long-term safety data and concerns about cardiovascular and breast cancer risks. Testosterone is generally not recommended for women with a history of breast cancer, since it can convert to estrogen in the body and potentially fuel certain cancers.
Safety Considerations
Excessive testosterone exposure can cause acne and increased hair growth, physicians said, while rarer effects such as voice deepening and hair loss may be irreversible. Studies show testosterone therapy is generally considered safe for men with medically diagnosed low hormone levels when properly prescribed and monitored, and the FDA removed a boxed cardiovascular warning from men’s testosterone products last year following post-marketing studies.
Outlook
Whether the FDA moves toward approving a female-specific testosterone product will likely depend on the evidence gathered during the public comment period, which closes on October 19, along with whether pharmaceutical companies pursue the additional Clinical Trials needed to address the long-term safety questions that have blocked approval in previous reviews.






Please wait processing your request...